Stay updated with breaking news from Stephan Jackman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Safety aspects of AL001 development may qualify for a 505 NDA pathway for FDA approval Alzamend recently completed a Phase IIA Study of AL001 in Alzheimer’s patients and healthy subjects...
Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA to initiate AL001-MDD01, a Phase IIA plasma/brain pharmacokinetics clinical study of AL001 for adjunctive treatment of patients with major depressive disorder (MDD).
02.10.2023 - Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) ... Seite 1
Alzamend Neuro Inc (NASDAQ: ALZN) received the FDA's "Study May Proceed" letter to initiate study AL001-BD01, a Phase 2A clinical study of AL001 for bipolar disorder type 1. The company expects the first patient to be dosed in the first quarter of 2024.
Alzamend’s recently completed Phase IIA study of AL001 in Alzheimer’s patients and healthy subjects identified a candidate dose that is unlikely to require therapeutic drug monitoring Safety...